Back to Journals » OncoTargets and Therapy » Volume 9

Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis

Total article views   Abstract views HTML views PDF downloads Totals
5,946 Dovepress* 4,206 882+ 922 5,088
PubMed Central* 0 858 355 858
Totals 4,206 1,740 1,277 5,946
*Since 4 August 2016
+Since July 2016

View citations on PubMed Central and Google Scholar